Chimeric nk receptor and methods for treating cancer
AssigneeTrustees of Dartmouth College
InventorsTong Zhang, Charles L. Sentman
Life of this patent
Estimating the term…
Abstract
The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
Claims20
A nucleic acid construct for expressing a chimeric receptor to reduce or eliminate a tumor comprising:
- a first nucleic acid sequence encoding a promoter operably linked to a second nucleic acid sequence encoding a chimeric receptor comprising a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif of SEQ ID NO:1.
2-7. (canceled)
A method for reducing or preventing tumors or preventing tumor reoccurrence in a in a human subject in need thereof comprising administering human immune cells which are engineered to express on their cell surface a chimeric receptor polypeptide comprising a C-type lectin-like type II natural killer cell receptor polypeptide fused to an immune signaling receptor polypeptide comprising SEQ ID NO:1, wherein said chimeric receptor is encoded by nucleic acid construct comprising (i) a first nucleic acid sequence encoding a promoter operably linked to (ii) a second nucleic acid sequence encoding a chimeric receptor polypeptide, wherein said second nucleic acid sequence comprises a nucleic acid encoding a C-type lectin-like type II natural killer cell receptor polypeptide fused to a nucleic acid encoding an immune signaling receptor polypeptide comprising SEQ ID NO:1, and further wherein the C-type lectin type II natural killer receptor polypeptide comprised in said chimeric receptor polypeptide binds a ligand expressed by tumor cells and activates said immune signaling receptor polypeptide comprising SEQ ID NO:
- 1 thereby eliciting an antitumor immune response in the treated subject.
Dependencies are inferred from the claim text.